Compare KPLT & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPLT | EQ |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.2M | 57.8M |
| IPO Year | N/A | 2018 |
| Metric | KPLT | EQ |
|---|---|---|
| Price | $7.36 | $1.27 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | $1.00 |
| AVG Volume (30 Days) | ★ 1.1M | 510.3K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $280,839,000.00 | $4,392,000.00 |
| Revenue This Year | $21.42 | N/A |
| Revenue Next Year | $15.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.15 | N/A |
| 52 Week Low | $5.08 | $0.27 |
| 52 Week High | $24.34 | $2.35 |
| Indicator | KPLT | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 62.36 |
| Support Level | $6.00 | $0.84 |
| Resistance Level | $7.00 | $1.44 |
| Average True Range (ATR) | 0.58 | 0.12 |
| MACD | 0.31 | 0.06 |
| Stochastic Oscillator | 35.88 | 74.52 |
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.